Small molecule antagonists of chemokine receptors - is promiscuity a virtue?

Current Topics in Medicinal Chemistry

Volumn 10, Issue 13, 2010, Pages 1351-1358

  Pease, James E ^a   Horuk, Richard ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antagonism; Chemokine receptors; Chemokines; GPCRs

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG MECHANISM; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PROTEIN FAMILY; RECEPTOR BLOCKING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; MOLECULAR CONFORMATION; MOLECULAR WEIGHT; RECEPTORS, CHEMOKINE; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 77955592736     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791561228     Document Type: Article

References (90)

1. Metchnikoff, E. Lectures on the Comparative Pathology of Inflammation, Keegan Paul, Trench, Trubner and Co.: Paternoster House, Charing Cross Road, 1893; p. 218.
2. van Creveld, S.; Paulssen, M. M. Significance of clotting factors in blood-platelets, in normal and pathological conditions. Lancet, 1951, 2, (6676), 242-244.
3. Zlotnik, A.; Yoshie, O.; Nomiyama, H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol., 2006, 7, (12), 243.
4. Murphy, P. M. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev., 2002, 54(2), 227-229.
5. Murphy, P. M.; Baggiolini, M.; Charo, I. F.; Hebert, C. A.; Horuk, R.; Matsushima, K.; Miller, L. H.; Oppenheim, J. J.; Power, C. A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev., 2000, 52(1), 145-176.
6. Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63(6), 1256-72.
7. Baggiolini, M. Chemokines and leukocyte traffic. Nature, 1998, 392(6676), 565-568.
8. Gerard, C.; Rollins, B. J. Chemokines and disease. Nat. Immunol., 2001, 2 (2), 108-15.
9. Alkhatib, G.; Combadiere, C.; Broder, C. C.; Feng, Y.; Kennedy, P. E.; Murphy, P. M.; Berger, E. A. CC CKR5: a RANTES, MIP- 1alpha, MIP-1beta receptor as a fusion cofactor for macrophagetropic HIV-1. Science, 1996, 272 (5270), 1955-1958.
10. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996, 272 (5263), 872-877.
11. Doranz, B. J.; Rucker, J.; Yi, Y. J.; Smyth, R. J.; Samson, M.; Peiper, S. C.; Parmentier, M.; Collman, R. G.; Doms, R. W. A dual-tropic primary HIV-1 isolate that uses fusin and the b chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell, 1996, 85(7), 1149-1158.
12. Dragic, T.; Litwin, V.; Allaway, G. P.; Martin, S. R.; Huang, Y.; Nagashima, K. A.; Cayanan, C.; Maddon, P. J.; Koup, R. A.; Moore, J. P.; Paxton, W. A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature, 1996, 381, 667-673.
13. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R. E.; Hill, C. M.; Davis, C. B.; Peiper, S. C.; Schall, T. J.; Littman, D. R.; Landau, N. R. Identification of a major co-receptor for primary isolates of HIV-1. Nature, 1996, 381, 661-666.
14. Ribeiro, S.; Horuk, R. Chemokine receptor antagonists from the bench to the clinic. Wiley-VCH: Weinheim, 2005; p 371-402.
15. Ribeiro, S.; Horuk, R. The clinical potential of chemokine receptor antagonists. Pharmacol. Ther., 2005, 107(1), 44-58.
16. MacArthur, R. D.; Novak, R. M. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis., 2008, 47(2), 236-241.
17. De Clercq, E. The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil). Biochem. Pharmacol., 2008, 77(11),1655-64.
18. Schwarz, M. K.; Wells, T. N. C. Recent developments in modulating chemokine networks. Expert Opin. Ther. Pat., 1999, 9, 1471-1489.
19. Gladue, R. P.; Zwillich, S. H.; Clucas, A. T.; Brown, M. F. CCR1 antagonists for the treatment of autoimmune diseases. Curr. Opin. Investig. Drugs, 2004, 5 (5), 499-504.
20. Zipp, F.; Hartung, H. P.; Hillert, J.; Schimrigk, S.; Trebst, C.; Stangel, M.; Infante-Duarte, C.; Jakobs, P.; Wolf, C.; Sandbrink, R.; Pohl, C.; Filippi, M. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology, 2006, 67, (10), 1880-3.
21. Vann, L. End of 2007 brings Extra Activity. Autoimmune Drug Focus, 2007, 37, 1.
22. Beaulieu, A.; Hasler, F.; Martin Mola, E.; Pavelka, K.; DeMartino, J.; Struthers, M.; Chen, P.; Koen, J.; Melian, A. The efficacy and safety of a CCR2 receptor antagonist in the treatment of rheumatoid arthritis (RA). Ann. Rheum. Dis., 2006, 65(2), 175.
23. Braddock, M. 11th annual inflammatory and immune diseases drug discovery and development summit 12-13 March 2007, San Francisco, USA. Expert Opin. Investig. Drugs, 2007, 16(6), 909-917.
24. Braddock, M. Advances in Anti-Inflammatory Therapeutics: 20-21 November 2006, London, UK. Expert Opin. Investig. Drugs, 2007, 16, (2), 257-261.
25. Johnson, M.; Li, A. R.; Liu, J.; Fu, Z.; Zhu, L.; Miao, S.; Wang, X.; Xu, Q.; Huang, A.; Marcus, A.; Xu, F.; Ebsworth, K.; Sablan, E.; Danao, J.; Kumer, J.; Dairaghi, D.; Lawrence, C.; Sullivan, T.; Tonn, G.; Schall, T.; Collins, T.; Medina, J. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg. Med. Chem. Lett., 2007, 17(12), 3339-3343.
26. Berry, K. Friedrich, M, Kersey, K, Stempien, MJ, Wagner, F, van Lier,; JJ, S. R, Wolk, K In Evaluation of T0906487, a CXCR3 antagonist, in a Phase 2a Psoriasis Trial, 12th International Conference, Inflammation Research Association, The Sagamore, Bolton Landing, NY, USA, October 3- October 7, 2004; The Sagamore, Bolton Landing, NY, USA, 2004.
27. Roche, O.; Schneider, P.; Zuegge, J.; Guba, W.; Kansy, M.; Alanine, A.; Bleicher, K.; Danel, F.; Gutknecht, E. M.; Rogers-Evans, M.; Neidhart, W.; Stalder, H.; Dillon, M.; Sjogren, E.; Fotouhi, N.; Gillespie, P.; Goodnow, R.; Harris, W.; Jones, P.; Taniguchi, M.; Tsujii, S.; von der Saal, W.; Zimmermann, G.; Schneider, G. Development of a virtual screening method for identification of frequent hitters in compound libraries. J. Med. Chem., 2002, 45(1), 137-142.
28. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov., 2004, 3(4), 353-359.
29. Rot, A.; Von Andrian, U. H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol., 2004, 22, 891-928.
30. Charo, I. F.; Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med., 2006, 354(6), 610-621.
31. Pease, J. E.; Williams, T. J. The attraction of chemokines as a target for specific anti-inflammatory therapy. Br. J. Pharmacol., 2006, 147(Suppl 1), S212-221.
32. Holmes, W. L. J.; Kuang, W. J.; Rice, G.; Wood, W. Structure and functional expression of a human interleukin08 receptor. Science, 1991, 253, 1278.
33. Murphy, P. M.; Tiffany, H. L. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science, 1991, 253(5025), 1280-1283.
34. Horuk, R. Chemokine receptors. Cytokine Growth Factor Rev., 2001, 12(4), 313-335.
35. Barnes, P. J. New molecular targets for the treatment of neutrophilic diseases. J. Allergy Clin. Immunol., 2007, 119(5), 1055-1062. quiz 1063-1064.
36. Strieter, R. M.; Keane, M. P.; Burdick, M. D.; Sakkour, A.; Murray, L. A.; Belperio, J. A. The role of CXCR2/CXCR2 ligands in acute lung injury. Curr. Drug Targets Inflamm. Allergy, 2005, 4 (3), 299-303.
37. Allegretti, M.; Bertini, R.; Cesta, M. C.; Bizzarri, C.; Di Bitondo, R.; Di Cioccio, V.; Galliera, E.; Berdini, V.; Topai, A.; Zampella, G.; Russo, V.; Di Bello, N.; Nano, G.; Nicolini, L.; Locati, M.; Fantucci, P.; Florio, S.; Colotta, F. 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J. Med. Chem., 2005, 48(13), 4312-4331.
38. Bizzarri, C.; Pagliei, S.; Brandolini, L.; Mascagni, P.; Caselli, G.; Transidico, P.; Sozzani, S.; Bertini, R. Selective inhibition of interleukin- 8-induced neutrophil chemotaxis by ketoprofen isomers. Biochem. Pharmacol., 2001, 61(11), 1429-1437.
39. Bertini, R.; Allegretti, M.; Bizzarri, C.; Moriconi, A.; Locati, M.; Zampella, G.; Cervellera, M. N.; Di Cioccio, V.; Cesta, M. C.; Galliera, E.; Martinez, F. O.; Di Bitondo, R.; Troiani, G.; Sabbatini, V.; D'Anniballe, G.; Anacardio, R.; Cutrin, J. C.; Cavalieri, B.; Mainiero, F.; Strippoli, R.; Villa, P.; Di Girolamo, M.; Martin, F.; Gentile, M.; Santoni, A.; Corda, D.; Poli, G.; Mantovani, A.; Ghezzi, P.; Colotta, F. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc. Natl. Acad. Sci. USA, 2004, 101(32), 11791-11796.
40. Villa, P.; Triulzi, S.; Cavalieri, B.; Di Bitondo, R.; Bertini, R.; Barbera, S.; Bigini, P.; Mennini, T.; Gelosa, P.; Tremoli, E.; Sironi, L.; Ghezzi, P. The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol. Med., 2007, 13(3-4), 125-33.
41. Zarbock, A.; Allegretti, M.; Ley, K. Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice. Br. J. Pharmacol., 2008, 155(3), 357-364.
42. Meyers, B. F. Keshavjee, S. Zamora, M.R. Davis, R.D. Smith, M.A. McFadden, P.M. Hertz, M.I. Daffonchio, L. Novellini, R. 405: A multicenter prospective, randomized, placebo-controlled trial of a CXCL8 inhibitor (reparixin) to prevent primary graft dysfunction after lung transplantation. J. Heart Lung Transplant., 2008, 27(2), S206-S207
43. Dwyer, M. P.; Yu, Y.; Chao, J.; Aki, C.; Chao, J.; Biju, P.; Girijavallabhan, V.; Rindgen, D.; Bond, R.; Mayer-Ezel, R.; Jakway, J.; Hipkin, R. W.; Fossetta, J.; Gonsiorek, W.; Bian, H.; Fan, X.; Terminelli, C.; Fine, J.; Lundell, D.; Merritt, J. R.; Rokosz, L. L.; Kaiser, B.; Li, G.; Wang, W.; Stauffer, T.; Ozgur, L.; Baldwin, J.; Taveras, A. G. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino} benzamide (SCH 527123): a potent, orally bioavailable CXCR2/ CXCR1 receptor antagonist. J. Med. Chem., 2006, 49 (26), 7603-7606.
44. Chapman, R. W.; Minnicozzi, M.; Celly, C. S.; Phillips, J. E.; Kung, T. T.; Hipkin, R. W.; Fan, X.; Rindgen, D.; Deno, G.; Bond, R.; Gonsiorek, W.; Billah, M. M.; Fine, J. S.; Hey, J. A. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J. Pharmacol. Exp. Ther., 2007, 322(2), 486-493.
45. Holz, O. Khalilieh, S. Ludwig-Sengpiel, A. Watz, H. Stryszak, P. Soni, P. Tsai, M. Sadeh, J. Magnussen, H., SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur. Respir. J., 2010, 35(3), 564-570.
46. Combadiere, C.; Ahuja, S. K.; Murphy, P. M. Cloning and functional expression of a human eosinophil CC chemokine receptor. J. Biol. Chem., 1995, 270, (28), 16491-16494.
47. Daugherty, B. L.; Siciliano, S. J.; DeMartino, J.; Malkowitz, L.; Sirontino, A.; Springer, M. S. Cloning, expression and characterization of the human eosinophil eotaxin receptor. J. Exp. Med., 1996, 183(5), 2349-2354.
48. Ponath, P. D.; Qin, S.; Post, T. W.; Wang, J.; Wu, L.; Gerard, N. P.; Newman, W.; Gerard, C.; Mackay, C. R. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J. Exp. Med., 1996, 183(6), 2437-2448.
49. Forssmann, U.; Uguccioni, M.; Loetscher, P.; Dahinden, C. A.; Langen, H.; Thelen, M.; Baggiolini, M. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J. Exp. Med., 1997, 185(12), 2171-2176.
50. Patel, V. P.; Kreider, B. L.; Li, Y.; Li, H.; Leung, K.; Salcedo, T.; Nardelli, B.; Pippalla, V.; Gentz, S.; Thotakura, R.; Parmelee, D.; Gentz, R.; Garotta, G. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J. Exp. Med., 1997, 185(7), 1163-1172.
51. White, J. R.; Imburgia, C.; Dul, E.; Appelbaum, E.; O'Donnell, K.; O'Shannessy, D. J.; Brawner, M.; Fornwald, J.; Adamou, J.; Elshourbagy, N. A.; Kaiser, K.; Foley, J. J.; Schmidt, D. B.; Johanson, K.; Macphee, C.; Moores, K.; McNulty, D.; Scott, G. F.; Schleimer, R. P.; Sarau, H. M. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J. Leukoc. Biol., 1997, 62(5), 667-675.
52. Kitaura, M.; Suzuki, N.; Imai, T.; Takagi, S.; Suzuki, R.; Nakajima, T.; Hirai, K.; Nomiyama, H.; Yoshie, O. Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J. Biol. Chem., 1999, 274(39), 27975-27980.
53. Shinkai, A.; Yoshisue, H.; Koike, M.; Shoji, E.; Nakagawa, S.; Saito, A.; Takeda, T.; Imabeppu, S.; Kato, Y.; Hanai, N.; Anazawa, H.; Kuga, T.; Nishi, T. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4- stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J. Immunol, 1999, 163(3), 1602-1610.
54. Sallusto, F.; Mackay, C. R.; Lanzavecchia, A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science, 1997, 277(5334), 2005-2007.
55. Romagnani, P.; De Paulis, A.; Beltrame, C.; Annunziato, F.; Dente, V.; Maggi, E.; Romagnani, S.; Marone, G. Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am. J. Pathol., 1999, 155(4), 1195-1204.
56. Gao, J. L.; Kuhns, D. B.; Tiffany, H. L.; McDermott, D.; Li, X.; Francke, U.; Murphy, P. M. Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor. J. Exp. Med., 1993, 177(5), 1421-1427.
57. Neote, K.; DiGregorio, D.; Mak, J. Y.; Horuk, R.; Schall, T. J. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell, 1993, 72(3), 415-425.
58. Sabroe, I.; Hartnell, A.; Jopling, L. A.; Bel, S.; Ponath, P. D.; Pease, J. E.; Collins, P. D.; Williams, T. J. Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J. Immunol., 1999, 162 (5), 2946-2955.
59. Fulkerson, P. C.; Fischetti, C. A.; McBride, M. L.; Hassman, L. M.; Hogan, S. P.; Rothenberg, M. E. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc. Natl. Acad. Sci. USA, 2006, 103(44), 16418-16423.
60. Campbell, E. M.; Kunkel, S. L.; Strieter, R. M.; Lukacs, N. W. Temporal role of chemokines in a murine model of cockroach allergen- induced airway hyperreactivity and eosinophilia. J. Immunol., 1998, 161(12), 7047-7053.
61. Blease, K.; Mehrad, B.; Standiford, T. J.; Lukacs, N. W.; Kunkel, S. L.; Chensue, S. W.; Lu, B.; Gerard, C. J.; Hogaboam, C. M. Airway remodeling is absent in CCR1-/- mice during chronic fungal allergic airway disease. J. Immunol., 2000, 165(3), 1564-1572.
62. Sabroe, I.; Peck, M. J.; Jan Van Keulen, B.; Jorritsma, A.; Simmons, G.; Clapham, P. R.; Williams, T. J.; Pease, J. E. A small molecule antagonist of the chemokine receptors CCR1 and CCR3: potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem., 2000, 275 (34), 25985-25992.
63. Naya, A.; Sagara, Y.; Ohwaki, K.; Saeki, T.; Ichikawa, D.; Iwasawa, Y.; Noguchi, K.; Ohtake, N. Design, synthesis, and discovery of a novel CCR1 antagonist. J. Med. Chem., 2001, 44, (9), 1429-35.
64. de Mendonca, F. L.; da Fonseca, P. C.; Phillips, R. M.; Saldanha, J. W.; Williams, T. J.; Pease, J. E. Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J. Biol. Chem., 2005, 280(6), 4808-4816.
65. Wise, E. L.; Duchesnes, C.; da Fonseca, P. C.; Allen, R. A.; Williams, T. J.; Pease, J. E. Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. J. Biol. Chem., 2007, 282(38), 27935-27943.
66. Amat, M.; Benjamim, C. F.; Williams, L. M.; Prats, N.; Terricabras, E.; Beleta, J.; Kunkel, S. L.; Godessart, N. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br. J. Pharmacol., 2006, 149 (6), 666-675.
67. Naya, A.; Kobayashi, K.; Ishikawa, M.; Ohwaki, K.; Saeki, T.; Noguchi, K.; Ohtake, N. Structure-activity relationships of 2-(benzothiazolylthio)acetamide class of CCR3 selective antagonist. Chem. Pharm. Bull., (Tokyo) 2003, 51(6), 697-701.
68. Naya, A.; Kobayashi, K.; Ishikawa, M.; Ohwaki, K.; Saeki, T.; Noguchi, K.; Ohtake, N. Discovery of a novel CCR3 selective antagonist. Bioorg. Med. Chem. Lett., 2001, 11(9), 1219-1223.
69. Kato, K. Yamamoto, M. Honda, S. Fujisawa, T. Diphenylmethane Derivatives As MIP-1α/RANTES Receptor Antagonists. WO-9724325, 1997.
70. De Lucca, G. V.; Kim, U. T.; Johnson, C.; Vargo, B. J.; Welch, P. K.; Covington, M.; Davies, P.; Solomon, K. A.; Newton, R. C.; Trainor, G. L.; Decicco, C. P.; Ko, S. S. Discovery and structureactivity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists. J. Med. Chem., 2002, 45(17), 3794-3804.
71. Charo, I. F.; Myers, S. J.; Herman, A.; Franci, C.; Connolly, A. J.; Coughlin, S. R. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. USA, 1994, 91, (7), 2752-2756.
72. Samson, M.; Labbe, O.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular cloning and functional expression of a new human CCchemokine receptor gene. Biochemistry, 1996, 35(11), 3362-3367.
73. Szekanecz, Z.; Szucs, G.; Szanto, S.; Koch, A. E. Chemokines in rheumatic diseases. Curr. Drug Targets, 2006, 7(1), 91-102.
74. Baba, M.; Nishimura, O.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Iizawa, Y.; Shiraishi, M.; Aramaki, Y.; Okonogi, K.; Ogawa, Y.; Meguro, K.; Fujino, M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA, 1999, 96(10), 5698-5703.
75. Seto, M.; Aikawa, K.; Miyamoto, N.; Aramaki, Y.; Kanzaki, N.; Takashima, K.; Kuze, Y.; Iizawa, Y.; Baba, M.; Shiraishi, M. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. J. Med. Chem., 2006, 49(6), 2037-2048.
76. Shiraishi, M.; Aramaki, Y.; Seto, M.; Imoto, H.; Nishikawa, Y.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Nishimura, O.; Baba, M.; Fujino, M. Discovery of novel, potent, and selective smallmolecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J. Med. Chem., 2000, 43(10), 2049-2063.
77. Dragic, T.; Trkola, A.; Thompson, D. A.; Cormier, E. G.; Kajumo, F. A.; Maxwell, E.; Lin, S. W.; Ying, W.; Smith, S. O.; Sakmar, T. P.; Moore, J. P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. USA, 2000, 97(10), 5639-5644.
78. Hall, S. E.; Mao, A.; Nicolaidou, V.; Finelli, M.; Wise, E. L.; Nedjai, B.; Kanjanapangka, J.; Harirchian, P.; Chen, D.; Selchau, V.; Ribeiro, S.; Schyler, S.; Pease, J. E.; Horuk, R.; Vaidehi, N. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol. Pharmacol., 2009, 75(6), 1325-1336.
79. Yang, Y. F.; Mukai, T.; Gao, P.; Yamaguchi, N.; Ono, S.; Iwaki, H.; Obika, S.; Imanishi, T.; Tsujimura, T.; Hamaoka, T.; Fujiwara, H. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur. J. Immunol., 2002, 32(8), 2124-2132.
80. Tokuyama, H.; Ueha, S.; Kurachi, M.; Matsushima, K.; Moriyasu, F.; Blumberg, R. S.; Kakimi, K. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int. Immunol., 2005, 17(8), 1023-1034.
81. Akashi, S.; Sho, M.; Kashizuka, H.; Hamada, K.; Ikeda, N.; Kuzumoto, Y.; Tsurui, Y.; Nomi, T.; Mizuno, T.; Kanehiro, H.; Hisanaga, M.; Ko, S.; Nakajima, Y. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation, 2005, 80(3), 378-384.
82. Akahori, T.; Sho, M.; Kashizuka, H.; Nomi, T.; Kanehiro, H.; Nakajima, Y. A novel CCR5/CXCR3 antagonist protects intestinal ischemia/reperfusion injury. Transplant. Proc., 2006, 38(10), 3366-3368.
83. Gao, P.; Zhou, X. Y.; Yashiro-Ohtani, Y.; Yang, Y. F.; Sugimoto, N.; Ono, S.; Nakanishi, T.; Obika, S.; Imanishi, T.; Egawa, T.; Nagasawa, T.; Fujiwara, H.; Hamaoka, T. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J. Leukoc. Biol., 2003, 73(2), 273-280.
84. Hersperger, R.; Janser, P.; Pfenninger, E.; Wuethrich, H. J.; Miltz, W. Chemokine receptor antagonists. WO/2005/077932, 2007.
85. Neidhart, W. Märki, H.P. Mohr, P. Conference Report, Frontiers in Medicinal Chemistry - Joint German-Swiss Meeting on Medicinal Chemistry. Chimia, 2009, 63 (9), 573-578.
86. Lagu, B.; Gerchak, C.; Pan, M.; Hou, C.; Singer, M.; Malaviya, R.; Matheis, M.; Olini, G.; Cavender, D.; Wachter, M. Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma. Bioorg. Med. Chem. Lett., 2007, 17(15), 4382-4386.
87. Mantovani, A. The chemokine system: redundancy for robust outputs. Immunol. Today, 1999, 20(6), 254-257.
88. Haldar, P.; Brightling, C. E.; Hargadon, B.; Gupta, S.; Monteiro, W.; Sousa, A.; Marshall, R. P.; Bradding, P.; Green, R. H.; Wardlaw, A. J.; Pavord, I. D. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med., 2009, 360(10), 973-984.
89. Nair, P.; Pizzichini, M. M.; Kjarsgaard, M.; Inman, M. D.; Efthimiadis, A.; Pizzichini, E.; Hargreave, F. E.; O'Byrne, P. M. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med., 2009, 360, (10), 985-93.
90. Leckie, M. J.; ten Brinke, A.; Khan, J.; Diamant, Z.; O'Connor, B. J.; Walls, C. M.; Mathur, A. K.; Cowley, H. C.; Chung, K. F.; Djukanovic, R.; Hansel, T. T.; Holgate, S. T.; Sterk, P. J.; Barnes, P. J. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet, 2000, 356(9248), 2144-2148.